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Host defense against infectious pathogens requires a coordinated
immune response. Traditionally innate immunity has been viewed as
generic and rapid, as lacking immunological memory and occurring
with similar magnitude on rechallenge while adaptive immunity is
more speciﬁc but requires time tomature. Innate immunity ismediated
by pattern recognition receptors (PRR, such as Toll-like receptors (TLR),
nucleotide-binding oligomerization domain protein like receptors
(NLR) and retinoic acid inducible gene 1 like receptors (RLR), that
recognize pathogen associatedmicrobial patterns (PAMPs) andmediate
an inducible response to micro-organisms (Yoneyama & Fujita, 2007;
Chen, Shaw, Kim,&Nuñez, 2009). PRR and the resulting cytokine signals
stimulate the production of transcription factors (TFs) that regulate sig-
nal transduction and effector responses. Functional specialization is
reﬂected by subsets of monocytes (Schmidl et al., 2014) and different
macrophage activation phenotypes (Mosser & Edwards, 2008).
Regulation of the inducible transcriptional program to pathogens
includes post-transcriptional control (Medzhitov & Horng, 2009). Tran-
scription of immune genes involves the interaction of promoter regions
with distant enhancers that are brought into close spatial alignment
through the looping out of interlinking DNA (Smale, 2010). These
distant enhancers are particularly important as binding sites for
tissue-speciﬁc TFs (Lee, Kim, Spilianakis, Fields, & Flavell, 2006). Several
DNA-binding proteins act synergistically to integrate the activation ofnder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
ticmanipulation during infectious diseases, Pharmacology & Therapeu-
2 J. Cole et al. / Pharmacology & Therapeutics xxx (2016) xxx–xxxmultiple signal transduction pathways and the generation of several
distinct TFs (Smale, 2010). The resulting complex of DNA-binding pro-
teins will ensure the acquisition of the chromatin remodeling factors,
transcription co-activators, general TFs and RNA polymerase II to acti-
vate gene transcription. This results in a relative stimulus and cell specif-
ic response. However, a growing body of literature suggests that the
conﬁguration of the chromatin structure of immune genes and their
regulatory elements is particularly important in determining the speci-
ﬁcity of the immune response (Smale, Tarkhovsky, & Natoli, 2014).
These chromatin changes are themselves directed in part by the inﬂu-
ences of lineage and cell-type speciﬁc TFs during cell development, as
exempliﬁed by themacrophage responses to the developmental regula-
tor PU-1 (Natoli, Ghisletti, & Barozzi, 2011). These cell-type speciﬁc in-
ﬂuences then interact with environmental inﬂuences to regulate gene
transcription in response to infection.
T-cell receptors and immunoglobulin are much more diverse than
PRR (Robins et al., 2009; Rothenberg, 2014). The development of
speciﬁc subsets, aids host defense (Luckheeram, Zhou, Verma, & Xia,
2012) and is regulated by speciﬁc TFs e.g. T-bet for T helper (Th) 1
(Lugo-Villarino, Maldonado-Lopez, Possemato, Penaranda, & Glimcher,
2003) and the retinoic acid receptor-related orphan receptor (ROR)
γT and RORαΤ for Th17 (Yang et al., 2008). B-cells can also be separated
into functional subsets with distinct transcriptional programs regulat-
ing their development (Allman & Pillai, 2008). Other lymphocyte sub-
sets function as having features more typical of innate immune cells
e.g. γδT-cells requiring the TF SOX13 for their development (Melichar
et al., 2007). Unique TF proﬁles also deﬁne subsets of NK cells (Fu
et al., 2014).
A key characteristic of both innate and adaptive effector functions is
that functional subsets demonstrate signiﬁcant plasticity, allowing a
more ﬂexible response to pathogens. Regulatory T-cells (Treg) can be-
come Th17, while other conditions allow them to develop into follicular
T helper cells (Tfh) (Xu, Kitani, Fuss, & Strober, 2007; Tsuji et al., 2009).
Th17 can become Th1 cells when exposed to IL-12 and Th2 cells in the
presence of IL-4 (Bending et al., 2009; Lee et al., 2009).
2. Epigenetic regulation of transcription
Epigenetics is deﬁned as a “ stably heritable phenotype resulting
from changes in a chromosome without changes in the DNA sequence”
(Berger, Kouzarides, Shiekhattar, & Shilatifard, 2009). The term epige-
netic is, however, increasingly taken to include transient chromatin
modiﬁcations as long as they result in altered gene transcription
(Natoli, 2010). Epigenetic changes play a pivotal role in the adaptation
of the transcriptional response (Jenuwein & Allis, 2001). Mechanisms
include DNA methylation, histone post-translational modiﬁcations
(PTMs), long non-coding RNA and microRNA.
Histone PTMs have been the subject of particularly intensive investi-
gation and we will focus on these in this review since these dynamic
changes allow modulation of the immune response to infection, even
though these are not necessarily inheritable.
Although these modiﬁcations may be transient they are more
sustained than the transient protein PTMs observed with signaling
molecules and thus allow a mechanism for extending the response
period to external stimuli (Ivashkiv, 2013). Histone octamers composed
of pairs of histone proteins H2A, H2B, H3 and H4 form nucleosomes
(Olins & Olins, 2003). Histone PTMs refer to the chemical alteration
predominantly of the N-terminal tail of the histones including, but
not limited to, acetylation, methylation, phosphorylation, and
ubiquitination. These chemical modiﬁcations control access of proteins
to the underlying DNA or the terminal tail of the histones, and therefore
regulate gene transcription (Shahbazian & Grunstein, 2007). The effect
on gene transcription of a given PTM can vary, for example methylation
of lysine or arginine residues can enhance or inhibit transcription
depending on the residue modiﬁed and the degree of methylation
(Kouzarides, 2007). These histone PTMs are regulated by families ofPlease cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013enzymes which have the potential to be therapeutically targeted;
histone acetyl transferases (HATs) and histone deacetylases (HDACs)
regulate acetylation while lysine or arginine methyltransferases, lysine
demethylases, arginine deaminases and arginine demethylases regulate
methylation status (Kouzarides, 2007). The concept of the epigenetic
landscape has been introduced to reﬂect the overall inﬂuence of DNA
methylation status, histone PTMs and proteins pre-bound to promoter
and enhancer regions on the accessibility for binding of classic signaling
TFs like NF-κB (Ivashkiv, 2013). This mechanism allows gene transcrip-
tion to respond to the environment, including stimuli from infection
(Jenuwein & Allis, 2001) (summarized in Fig. 1). The histone response
is therefore a dynamic sensor of the cell's environment. As such
epigenetic manipulation makes for an attractive therapeutic target as
it allows for a reversible modiﬁcation in host gene expression.
3. Innate immunity
Many pathogens colonize the host prior to establishing invasive
disease, as illustrated by extracellular bacteria (Kadioglu et al., 2008)
but similar principles apply for fungi and parasites. The interactions
between the innate immune system and the pathogen are a key factor
in determining susceptibility to disease and likelihood of clinical infec-
tion (Dockrell, Whyte, & Mitchell, 2012). This is clearly dependent on
how effective the transcriptional response of innate immune cells is,
particularly macrophages as orchestrators of the innate immune re-
sponse. These early responses are also important for intracellular path-
ogens such as viruses and bacteria.
3.1. Macrophage activation
Macrophages represent the cornerstone of the innate immune
response in tissues (Twigg, 2004; Aberdein, Cole, Bewley, Marriott, &
Dockrell, 2013). Resident macrophages, originating from a fetal origin
are supplemented by monocyte-derived macrophages recruited to
sites of inﬂammation (Shi & Pamer, 2011). Macrophages have been de-
scribed as either “classically” activated macrophages (M1 phenotype),
that are particularly important for the immune response to intracellular
bacteria, and generate increased levels of reactive oxygen species (ROS),
nitric oxide (NO) (Dalton et al., 1993), or as “alternatively” activated
macrophages (M2 phenotype) that play key roles in wound healing
but also immunity to helminths and other parasites (Anthony et al.,
2006) (Mosser & Edwards, 2008). In reality every stimulus results in a
slightly different transcriptional proﬁle (Murray et al., 2014) and activa-
tion states are highly plastic (Daigneault, Preston, Marriott, Whyte, &
Dockrell, 2010). Given the different impact on disease processes modu-
lation of the activation-associated transcriptional proﬁle represents a
potential therapeutic approach that can promote resolution of inﬂam-
mation and tissue repair or increase pathogen clearance.
3.2. Epigenetic modiﬁcation and macrophage differentiation
The differentiation processes driving monocytes to become macro-
phages or dendritic cells have been extensively studied (Saeed et al.,
2014) and comprehensive review of the subject can be found
(Álvarez-Errico, Vento-Tormo, Sieweke, & Ballestar, 2014). Myeloid dif-
ferentiation is characterized by DNAhypomethylation, although it is dy-
namically regulated (Bocker et al., 2011). It also involves changes in
histone PTMs and HDAC7, which represses macrophage speciﬁc genes,
is repressed by the lineage speciﬁc TF CCAAT/enhancer binding
protein-α (C/EBPα) that acts in concert with the PU-1 TF to promote
macrophage differentiation (Barneda-Zahonero et al., 2013). Recently,
mass spectrometry approaches have been utilized to identify histone
PTMs occurring during the differentiation process frommonocyte to ei-
ther dendritic cell or macrophage. The results demonstrated that the
macrophage differentiation process is associatedwith the combinatorial
modiﬁcation lysine 9methylation, serine 10 phosphorylation and lysineticmanipulation during infectious diseases, Pharmacology & Therapeu-
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Fig. 1. Schematic representation of the main epigenetic mechanisms. a) the presence of favorable PTM (such as acetylation) on the histone tail allows the binding of TFs in turn attracting
RNApolymerase.b) This vignette illustrates themode of action ofmicroRNA inhibiting the binding of RNApolymerase and or the trafﬁcking ofmRNA. c) Illustrates the removal of PTMs by
specialized enzymes (such as HDAC) in turn modiﬁes the conﬁrmation of the chromatin and inhibits the binding of TFs and RNA polymerase. d) In addition DNA methylation blocks the
binding of TFs thereby inhibiting gene transcription from occurring.
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ferentiation to a dendritic cell was associated with acetylation of lysine
16 on histone H4 (Nicholas et al., 2014). This suggests that distinct his-
tone PTMsoccur during differentiation, in a cell-type speciﬁcmanner. In
addition genome wide studies show how the lineage TF PU-1 facilitates
nucleosome remodeling and co-operates with other small subsets
of lineage speciﬁc TFs to enable H3 lysine 4 monomethylation
(H3K4me1) at a range of gene regulatory elements. These then act as
beacon sites for the recruitment of further regulators that ultimately
ensure the cell speciﬁc transcriptional response (Heinz et al., 2010).
These differences may allow differential regulation of signature
inﬂammatory responses important in responses to pathogens. The
exposure of immature macrophages to trichostatin A (TSA) (a class I
and II HDACi) leads to increased global levels of H3 and H4 acetylations.
This results in an increase in the release of the pro-inﬂammatory cyto-
kine TNF-α. However, this effect is not seen inmaturemacrophages sug-
gesting that this reversible chromatin modiﬁcation and its capacity to
inﬂuence TNF-α expression are only present during a ﬁxed window of
the maturation process (Lee, Kim, Sanford, & Sullivan, 2003). Thus the
maturation process inﬂuences the cell's epigenetic proﬁle and alters
the ability of certain modiﬁcations to act as regulation points for cyto-
kine responses. In this case monocytes, cells known to generate high
level TNF-α responses (Daigneault et al., 2010), are equipped with the
ability to regulate TNF-α responses by global reduction in both total
H3 and H4 acetylation patterns but tissue macrophages which have
less high output expression of TNF-α have lost this regulation check-
point (Lee et al., 2003). These differentiation-dependent points of regu-
lation involving histone PTMs may in turn be inﬂuenced by prior
experience.
The relationship between histone PTMs and gene expression does
not conclusively demonstrate directionality. This is illustrated by the
case of differentiation and whether histone PTMs are a consequence of
gene activation during differentiation or a key driver of the differentia-
tion process has been debated.
Nevertheless the example of TSA inﬂuencing acetylation levels in
monocytes prior to differentiation suggests that alterations of histonePlease cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013PTMs precede differentiation and inﬂuence the process (Lee et al.,
2003). The epigenetic regulation of the processes governing differentia-
tion of monocytes could therefore represent a target with which
to inﬂuence macrophage phenotype and the microbicidal and inﬂam-
matory responses during infection.
3.3. Chromatin remodeling and macrophage transcriptional proﬁles
The different macrophage activation states have different transcrip-
tional proﬁles (Ehrt et al., 2001) and different signatures of histone
PTMs (De Santa et al., 2009; Satoh et al., 2010). In general gene loci
associatedwith polarization state ofmacrophagesmay be in a repressed
state, characterized by the presence of repressive marks such as H3
lysine 9 trimethylation (H3K9me3) and H3K27me3 and heterochroma-
tin. In a poised state the abovementioned repressive marks are found in
associationwithmarks such asH3K4me3 andH3K9, 14-acetylation (ac)
and the chromatin structure is partially openwhile in an active state the
repressive marks are removed and active marks, such as H3K4me3,
histone 3 serine 10 phosphorylation (H3S10phos) and histone 4 acety-
lation (H4ac) are present, allowing formation of euchromatin and gene
transcription (Ivashkiv, 2013). In differentiated macrophages TFs such
as PU-1 and C/EBPα open the regulatory regions. Even resting macro-
phages have acquired permissive marks on promoters and enhancers
can be in a poised state. Basal transcription of pro-inﬂammatory
cytokines (e.g. TNFα) occurs but is kept restrained without appropriate
activation by mechanisms that include recruitment of HDACs and
histone demethylases.
During the initiation of classical activation, the transcription
start sites of genes associated with pro-inﬂammatory responses to lipo-
polysaccharide (LPS are found to have an increase in H3K4me3 at gene
promoters, associatedwith increased gene transcription (De Santa et al.,
2009). Histone modiﬁcations also poise gene enhancers to facilitate
rapid activation following subsequent LPS stimulation (Smale et al.,
2014). H3K4me3 and H3Kac have been associated with epigenetic
changes at a range of cytokine promoters such as Tnfa, Il6 and Ifnb
(Ivashkiv, 2013). These changes contribute to the cell speciﬁcity of theticmanipulation during infectious diseases, Pharmacology & Therapeu-
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be a feature of enhancers in a poised state and is enriched in both
inactive poised enhancers (where it occurs in the absence of histone
acetylation) and active enhancers (where it occurs in the presence of
histone acetylation) (Creyghton et al., 2010; Rada-Iglesias et al., 2011).
The H3K4me1 mark also plays a role in latent enhancers (Ostuni et al.,
2013). These transcriptional enhancers have been deﬁned as lacking
marks and TF binding at baseline in differentiated cells, acquiring the
mark and TF binding following stimulation, requiring both stimulus
dependent and lineage speciﬁc TFs, retaining the H3K4me1 mark after
stimulation cessation and enhancing subsequent responses following
secondary stimulation. The persistence of H3K4me1 as a stable mark
has been demonstrated in a subset of interferon gamma (IFN-γ)
regulated genes in macrophages and can enable innate memory
through enhanced responses on re-stimulation.
Active enhancers frequently recruit p300, a protein that contains a
histone acetyltransferase domain (Heintzman et al., 2009; Chen & Li,
2011). p300 is found bound to a large group of enhancers with the
H3K4me1 mark, that are activated by LPS in murine bone-marrow
derived macrophages (Ghisletti et al., 2010). These enhancers also
contain binding sites for the lineage restricted TF PU-1, which is critical
in maintaining the H3K4me1 mark. Stimulus speciﬁcity in macrophage
transcriptional responses can involve TF co-operativity but chromatin
remodeling also plays a role (Smale et al., 2014). LPS also stimulates
de novo enhancers involving H3K4 methylation, mediated by the
histone methyltransferases MLL1, 3 and 4 that work in co-operation
with the TFs PU-1, C/EBPs and NF-κΒ (Kaikkonen et al., 2013). Histone
acetylation appears to precede these H3K4 methylation events. Gene
transcription following active stimulation also requires activation of
enzymes that can remove repressive marks; LPS-induced induction
of H3K4me3 results in preferential recruitment of the histone
demethylase Jumonji domain-containing 3 (JMJD3) that in turns leads
to loss of the repressive H3K27me3 mark (De Santa et al., 2009).
There are many variations in how speciﬁc enzymes regulate the
transcription of various genes; HDAC3 enhances IL-6 responses to
LPS, and also regulates IFN-β (Chen et al., 2012), while its loss favors
alternative activation in macrophages (Mullican et al., 2011). JMJD3
also facilitates removal of repressive marks on genes associated with
alternative activation (Ishii et al., 2009; Satoh et al., 2010). However
the increasing identiﬁcation of speciﬁc genes that regulate the epigenetic
events controlling the magnitude and kinetics of pro-inﬂammatory
signaling offer the potential to modify these responses when excessive
or inadequate through therapeutic targeting of this process.
Some transcriptional responses to LPS are associatedwith genes that
have CpG island promoters and these genes have open chromatin in an
unstimulated state that facilitates rapid but transient induction of
the gene (Smale et al., 2014). Other LPS responses involve genes with
promoters containing low CpG promoters. These genes usually have
chromatin that appears in an inactive state in the unstimulated state
and gene activation requires chromatin remodeling by SWItch/Sucrose
Non-fermentable SWI/SNF nucleosome remodeling complexes (Smale
et al., 2014). LPS responsive genes that require some chromatin remod-
eling by this mechanism include the IL-6, IL-12b and inducible nitric
oxide synthase (NOS2) genes. These responses are associated with
different kinetics of nuclear factor-κΒ (NF-κΒ) binding and more
sustained and higher level transcription. As an example of this mecha-
nism it has been shown that chromatin remodeling allows access of
c-Rel-containingNF-κΒ to the IL-12b promoter (Weinmann et al., 2001).
The different macrophage polarization states are characterized
by differences in their metabolic proﬁle; LPS-stimulated macrophages
activate glycolysis and suppress oxidative phosphorylation and mito-
chondrial respiration, and accumulate the tricarboxylic acid cycle inter-
mediate succinate, which stabilizes the TF, hypoxia-inducible factor
(HIF)-1α, leading to enhanced release of thepro-inﬂammatory cytokine
IL-1β (Tannahill et al., 2013). This proﬁle is also associated with
decreased activation of silent mating type information regulator 2Please cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013homolog (SIRT) 5 (Tannahill et al., 2013), which acts as a deacetylase
and a desuccinylase. This has the potential to modify histone PTMs
involving acetylation and succinylation and alter chromatin modeling
(Haigis & Sinclair, 2010; Park et al., 2013). The sirtuins are a family of
highly conserved NAD dependent histone deacetylases and are meta-
bolic sensors (Shih & Donmez, 2013; Papanicolaou, O'Rourke, & Foster,
2014). Sirtuin activity links diurnal variation in metabolism to inﬂam-
matory responses regulated by the circadian clock machinery (Verdin,
2014). As a mitochondrial sirtuin, SIRT 5, has the potential to link met-
abolic changes to chromatin remodeling. Monocytes stimulated with
LPS orβ-glucanwere observed to have lower levels of oxygen consump-
tion suggesting a shift to glycolysis. It was shown in macrophages that
the control of these metabolic processes was in part regulated by epige-
netic modiﬁcations involving loss of H3K27ac and increase in
H3K4me3 at the promoter sites for genes involved in metabolic re-
sponses, in particular the mammalian target of rapamycin (mTOR)
(Cheng et al., 2014). Moreover following challenge with β-glucan
mice demonstrated HIF-1α-dependent protection against Staphylococ-
cus aureus, associated with a shift to glycolysis and upregulation of
JHDM1D ((Jumonji C domain-containing histone demethylase), illus-
trating another potential mechanism linking shifts in metabolism to
epigenetic changes that enhance the innate immune response to infec-
tion (Cheng et al., 2014). It has been suggested that pro-inﬂammatory
cells, such as M1 activated macrophages and Th17 cells are character-
ized by an increased reliance on glycolysis whereas cells with a more
anti-inﬂammatory proﬁle or resting cells such as the M2 macrophage,
Treg and T memory cells are more reliant on oxidative metabolism
(O'Neill & Hardie, 2013). Finally, acetylCoA derived from the metabo-
lism of pyruvate is the principal acetyl donor for histone acetylation
(Wellen et al., 2009).
3.4. Macrophage training and tolerance
The concept of trained immunity and tolerance has been debated
but has emerged as a framework to explain the potential existence of
innate immune memory. The process by which prior stimulation with
β-glucan and BCG enhance responsiveness and protection to subse-
quent infectious challenge, has been termed trained immunity (Netea,
Quintin, & van der Meer, 2011). Recent studies have linked innate im-
mune memory to the formation of latent enhancers that are unmarked
in the basal state and becomemarked following initial exposure to stim-
uli, but the persistence of one key mark, H3K4me1, at latent enhancers,
has only been determined for relatively short time spans in vitro (Ostuni
et al., 2013), so the long term impact of this mechanism remains to be
determined.
Early observations showed increased survival from infection with
Babesia microti in mice vaccinated with Bacille Calmette–Guerin (BCG)
(Clark, Allison, & Cox, 1976). This observation of enhanced response fol-
lowing initial exposure has been seen in a number of different systems
including plants, where it is known as systemic acquired resistance
(Durrant & Dong, 2004). Recently, animal studies have shown that the
mechanisms governing this enhanced response may involve epigenetic
changes.Micewere found to be protected from subsequent re-exposure
with lethal doses of Candida albicans (Quintin et al., 2012). The training
required theβ-glucan receptor dectin-1 and the Raf-1 pathway andwas
associated with increases in H3K4me3 (Quintin et al., 2012). Chromatin
immunoprecipitation and sequencing (Chip-seq) analysis demonstrated
that the H3K4me3 mark was associated with the promoters of genes
involved in immune responses including dectin-1, C-type lectin
receptors, pro-inﬂammatory cytokines such as TNF-α, IL-6 and IL-18,
TLRs and the TLR adaptor protein Myd88. In studies of human subjects
who had received BCG vaccination, macrophages were found to have
increased TNF-α and IL-1β productionwhen re-exposed tomycobateria
or C. albicans (Kleinnijenhuis et al., 2012). This mechanism affords
the host the ability to adapt to its environment and represents a form
of innate immune memory resulting from chromatin remodeling.ticmanipulation during infectious diseases, Pharmacology & Therapeu-
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macrophages, exposed to TLR2 agonists prior to differentiation, demon-
strate lower levels of ROS production following subsequent stimulation
(Yáñez et al., 2013), suggesting that epigenetic changes in macrophages
may be sustained for prolonged periods. Other innate immune cells such
as NK cells can also develop sustained immunologicalmemory following
sensitization to mediate contact hypersensitivity in mice (O'Leary,
Goodarzi, Drayton, & von Andrian, 2006). Moreover, BCG vaccination
was shown to lead to increased pro-inﬂammatory cytokine production
(IL-1β, IL-6 and TNF-α) when NK cells were stimulated ex vivo
(Kleinnijenhuis et al., 2014).
In contrast to a heightened response associated with training, it has
long been established that macrophages can become tolerant following
LPS challenge, leading to a decreased responsiveness to LPS and other
stimuli on rechallenge. Clinically this phenotype is demonstrated
by the immune paralysis associated with critical illness and sepsis.
Mice pre-treated with LPS demonstrated increased survival in a
polymicrobial model of sepsis caused by cecal ligation and puncture
(Wheeler et al., 2008). Tolerance can be induced by repeated exposure
to TLR4 agonists such as LPS, whereas the response to other stimuli
induces the enhanced pro-inﬂammatory response seen in trained
immunity (Ifrim et al., 2014). Tolerance is also associated with speciﬁc
changes in the epigenetic state of cells in particular decreased H4ac
(Foster, Hargreaves, & Medzhitov, 2007). The non-speciﬁc innate im-
mune memory provided by training and tolerance can be viewed as
an adaptation to help ensure inﬂammatory responses to pathogens
are appropriate but not excessive. Tolerance helps decrease the risk of
tissue injury and death from an exaggerated immune response to infec-
tion. As such themanipulation of these states represent a potential ther-
apeutic approach to limit excessive inﬂammation and potentially
improve bacterial clearance from a previously stimulated macrophage.
A more recent analysis has compared the histone marks associated
with differentiation of macrophages frommonocytes after the develop-
ment of β-glucan induced training or LPS-induced tolerance (Saeed
et al., 2014). Dynamic changes in H3K27ac in training and tolerance
with a subset of responses thatwere unique to tolerancewere observed.
Sites of histone methylation were more constant and marked pro-
moters or enhancers were susceptible to dynamic acetylation at
H3K27. The transcription proﬁle of tolerance was associated with
modules typically seen in monocytes but not naïve macrophages, in-
cluding surprisingly some pro-inﬂammatory genes, but it also in-
cluded transcription of some negative regulators of inﬂammatory
responses such as IL-1 receptor-associated kinase 3 (IRAK3), a nega-
tive regulator of TLR signaling. Training resulted in upregulation of
molecules seen in naïve macrophages, including those involved in
metabolism.
A separate phenomenon that appears distinct from tolerance is
seen when immune cells are rechallenged with certain toxins. This
phenomenon, which has been described for anthrax lethal toxin, is
termed toxin-induced resistance. When macrophages are exposed
to a sub-lethal dose of the toxin they are then resistant to the cytolyt-
ic effects of higher potentially lethal doses on rechallenge. A
small proportion of macrophages (2–4%) can retain this resistance
for 5–6weeks and themechanism of this phenomenon appears to in-
volve HDAC8 (Ha, Han, Reid, & Kim, 2014). HDAC8 reduced H3 lysine
27 acetylation. This suggests that modulating enzymes regulating
epigenetic processes could also inﬂuence the response to microbial
toxins.
Overall awealth of information on the role of epigenetic responses in
regulating innate responses, particularly in macrophages is emerging.
However, if these are to be exploited therapeutically clariﬁcation is
still required on how long the changes documented in vitro last
in vivo, clariﬁcation of which enzymes regulating histone PTMs have
the degree of speciﬁcity to allow their selective modulation and ﬁnally
identiﬁcation of which processes have signiﬁcant enough functional
consequences to justify their targeting.Please cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.0134. Epigenetic changes and adaptive immune responses
The regulation of the adaptive immune system also involves
epigenetic modiﬁcations (Cuddapah, Barski, & Zhao, 2010). Lympho-
cytes are poised to respond to antigen recognitionwith a transcriptional
program that involves genes, regulating metabolism, proliferation and
clonal expansion. The epigenetic landscape is essential for lymphocyte
subset specialization while metabolic regulation is critical to the devel-
opment of immunological memory (Chang, Wherry, & Goldrath, 2014).
Resting naïve T-cells have low levels of glycolysis, but after encounter-
ing a foreign antigen the differentiating T-cell increases its reliance on
aerobic glycolysis, (DeBerardinis, Lum, Hatzivassiliou, & Thompson,
2008). Both the AMP activated protein kinase (AMPK) and mTOR are
the key in controlling T-cell metabolic activity (Michalek et al., 2011).
Th1 cells are required to control intracellular pathogens, Th2 cells to
respond to parasites and Th17 cells for antibacterial roles at mucosal
surfaces (Kanno, Vahedi, HiraHara, Singleton, & O'Shea, 2012). It has
been shown that these different lineages are associated with different
acetylation status at of the promoter regions of IL-4 and IFN-γ genes
(Messi et al., 2003). Moreover, the promoter regions of certain genes
such as IL-4 and IFN-γ are associated with H3K4me3 and H3K27me3
in a lineage speciﬁc manner (Wei et al., 2009).
CD8+ T-cells provide one of the best examples of epigenetic regula-
tion in the immune systems. Cd4 gene silencing involves epigenetic
mechanisms since it persists even after deletion of the transcriptional
silencer during thymocyte development (Zou et al., 2001; Tanuchi
et al., 2002). During the development of memory CD8+ T-cells, there
is an increase in the levels of acetylation on H3K9 and K14 (DiSpirito
& Shen, 2010). This results in a number of genes being poised for
translation allowing a faster response on re-exposure. Furthermore,
the rapidly inducible genes of poised lymphocytes are associated with
H3 acetylation and H3K4me3 modiﬁcations in their promoter regions
(Roh, Cuddapah, Cui, & Zhao, 2006). Thus there are theoretical opportu-
nities to modify immune responses to pathogens and vaccines through
epigenetic manipulation of lymphocyte subsets.
5. Epigenetics and non-viral infections
The importance of epigenetic changes occurring as part of the path-
ogenesis of infectious diseases is becoming increasingly understood
(Bierne, Hamon, & Cossart, 2012). A range of micro-organisms induce
epigenetic modiﬁcations during infection (Table 1). These includeMy-
cobacterium tuberculosis (Yaseen, Kaur, Nandicoori, & Khosla, 2015), Shi-
gella ﬂexneri (Harouz et al., 2014) and the rickettsial pathogen
Anaplasma phagocytophilum (Garcia-Garcia, Barat, Trembley, & Dumler,
2009).
Changes in histone PTM, DNA methylation and miRNAs all play a
role in the response to infection. Indeed miRNAs are induced following
exposure to LPS (Taganov, Boldin, Chang, & Baltimore, 2006) and by a
range of different bacterial pathogens including Listeria monocytogenes
(Schnitger et al., 2011), Helicobacter pylori (Zhang et al., 2008) and
M. tuberculosis (Rajaram et al., 2011). The role of miRNAs in response
to infection has recently been reviewed (Staedel & Darfeuille, 2013;
Maudet, Mano, & Eulalio, 2014) and as our focus has been on discussion
of histone PTMs and their therapeutic potential we will not discuss
these further. Furthermore, sites of DNA methylation have also been
shown to be activelymodiﬁed during infection (Pacis et al., 2015). Alter-
ations inDNAmethylation proﬁles can be identiﬁed following infections
with agents such asM. tuberculosis and differences can be observed in
patients with latent, as opposed to active TB, raising the possibility
that they could be used as biomarkers of infection (Esterhuyse et al.,
2015).
Epigenetic mechanisms can also be employed by pathogens to
regulate their gene transcription. DNA methylation varies between
Salmonella enterica serovars and may inﬂuence virulence (Pirone-
Davies et al., 2015). HDACs modulate the transcriptional responses ofticmanipulation during infectious diseases, Pharmacology & Therapeu-
Table 1
Host-pathogen interactions and histone post-translational modiﬁcations.
Organism Mechanism Enzyme Histone PTM Consequence References
Mycobacteria
Mycobacterium tuberculosis Secreted mycobacterial protein Rv1988 Methyltransferase Methylates histone H3 at arginine 42 Represses gene expression leading to decreased
production of ROS, NOS and NADPH oxidase
Yaseen et al., 2015
Bacteria
Legionella pneumophilia Secretes RomA Methyltransferase Trimethylates lysine 14 Decreased immune gene transcription in
particular IL-6 and TNF-α
Rolando et al., 2013
Listeria monocytogenes Secretes lysteriolysin O and internalin B Dephosphorylation Deacetylation of lysine 18 Decreased immune gene transcription Hamon et al., 2007
Deacetylation via
translocation of sirt2
Eskandarian et al., 2013
Helicobacter pylori Unclear but involves cytotoxin-
associated gene A pathogenicity island
Dephosphorylation of serine10, decreased
acetylation of lysine 23
Increased inﬂammation and IL-8 production,
and upregulation of oncogene c-Jun
Ding et al., 2010
Escherichia coli LPS stimulation of TLR Acetylation Histone H3 lysine 14 and H4 lysine 8
hyperacetylation
Increased inﬂammation Modak et al., 2012
Shigella ﬂexneri Injected OspF Phospholyase Phosphorylates heterochromatin Protein 1 γ
at serine 83
Modulates gene expresion in particular IL-8
and cell proliferation
Harouz et al., 2014
Anaplasma phagocytophilum Secretes ankyrin A Deacetylation Deacetylation of histone H3 Decrease in host defense genes including
cytochrome B-245, beta polypeptide.
Garcia-Garcia et al., 2009
Virus
Human cytomegalovirus Regulation of DOT1L Methyltransferase Histone H3 K79 dimethylation and H4 lysine
16 deacetylation
Decreased gene expression O'Connor, DiMaggio,
Shenk, & Garcia et al.,
2014
HIV HIVssRNA TLR8 mediated Histone H4 acetylation and H3 lysine 4
trimethylation, decrease in lysine 27
trimethylation
TNF-α release Han et al., 2012
Human adenovirus Early region 1a Deacetylation Histone H3 lysine 18 Oncogenic transformation Oh, Traktman, & Knipe,
2015
Inﬂuenza A virus Secretes NS1 histone like mimic Cytosolic signaling human PAF1 transcription
elongation complex
Reduces antiviral gene expression Marazzi et al., 2012
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tozoan Entamoeba histolytica employs H3 lysine 27 dimethylation
(H3K27me2) as a repressive mark to enable transcriptional gene
silencing (Foda & Singh, 2015).
5.1. Epigenetics and bacteria
Examples of pathogens alteringhost gene transcription bymodifying
the host cell's epigenome via modulation of histone PTM have been
provided by Legionella pneumophilia, H. pylori and L. monocytogenes
(Hamon et al., 2007; Ding et al., 2010; Rolando et al., 2013). When
gastric epithelial cells were infected with H. pylori, a time dependent
dephosphorylation of H3S10 was observed as well as a decrease in
H3K23ac (Ding et al., 2010). Production of IL-8 in response to H. pylori
of these epithelial cells was reduced by TSA, suggesting that it involved
histone deacetylation events. Interestingly, this mechanism is likely to
be both organism and cell speciﬁc since in THP-1 cells the dephosphor-
ylation of H3S10 was associated with the IL-6 promoter and resulted in
an increase in IL-6 transcription (Pathak et al., 2006). The exact mecha-
nism by which H. pylori causes alterations in histone PTM change is not
fully understood, although it is apparent that it involves the cytotoxin-
associated gene A pathogenicity island (cagPAI), since deletion of this
but not cagA or other factors induced the dephosphorylation of H3S10
(Ding et al., 2010). These changes were also associated with upregula-
tion of the oncogene c-Jun and with downregulation of heat shock pro-
tein (hsp) 70, showing that they not only contribute to inﬂammation
but potentially also tumor development, which in the case of hsp70
the authors suggested was related to reduced protection against stress-
induced protein denaturation and aggregation. Fehri et al. showed that
H. pylori infection resulted in dephosphorylation of H3S10 but also
threonine at H3T3 in gastric epithelial cells (Fehri et al., 2009). These
events were also linked to the cagPAI and a functional type 4 secretion
system and were reversed by a DcagL mutant. The changes were associ-
ated with bacterial induced reduction of cell division cycle 25 (CDC25C)
phosphatase and a resultant reduction in activation of the H3 kinase
vaccinia-related kinase (VRK) I, which resulted in H. pylori induced
pre-mitotic arrest.
In the case of L. pneumophilia the bacterium uses a type 4 secretion
system effector, regulator of methylation A (RomA), a Suvar3–9,
enhancer-of-zeste, Trithorax (SET) domain-containing methyltransfer-
ase, which causes H3K14me3 of the host cell and reduces H3K14ac
(Rolando et al., 2013). This switches off gene transcription. The SET pro-
tein domain is 130 amino acids long, was ﬁrst identiﬁed in Drosophila,
and has been found in all eukaryotic organisms studied. All histone
methyltransferases contain a SET domain apart from those of the
DOT1 family (Dillon, Zhang, Trievel, & Cheng, 2005). Chip-seq data in
the study by Rollando et al. established that the switch to the repressive
mark H3K14me3 was associated with the promoter sites of genes in-
volved in immune responses, in particular cytokines such as TNF-α
and IL-6 and PRR such as TLR5, which responds to ﬂagellin, and the
Nod-like receptor Nalp 3 (Rolando et al., 2013). This provides support
to the theory that pathogens including bacteria and viruses can use
chromatin remodeling strategies to turn off immune responses. As
such this process of bacterial manipulation of the host gene expression
represents an interesting therapeutic approach as it would be possible
to either target RomA speciﬁcally to prevent the trimethylation of
H3K4 or use histone acetyl transferase or CRISPR-Cas9 (as discussed
below) to inhibit removal of the acetyl group.
A further example of epigenetic modulation is provided by
L. monocytogenes, that secretes the surface protein internalin B (InlB),
resulting in translocation of a host cell class 3 HDAC, sirtuin 2 (SIRT2),
to the nucleus. In this location SIRT2 deacetylates H3K18ac. This is
associated with a decrease in expression of genes involved in DNA-
binding and immune responses (Eskandarian et al., 2013). Moreover,
L. monocytogenes also secretes listeriolysin O (a pore-forming cytolysin),
which causes dephosphorylation of H3S10 and decreases the level ofPlease cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013H4ac (Hamon et al., 2007). These responses occurred by a pore-forming
independent mechanism. This correlates with a change in the transcrip-
tional proﬁle of HeLa cells, resulting in a decrease in genes involved in
innate immune responses, including the neutrophil chemokine CXCL2
and DUSP4 a phosphatase involved in regulating MAPK signaling.
A. phagocytophilum survives within neutrophils and their myeloid
precursors and has been shown to induce epigenetic changes in host
cells (Garcia-Garcia et al., 2009). Genes encoding antimicrobial peptides
and both enzymatic and oxidative host defensemolecules are downreg-
ulated in myeloid cell lines (neutrophilic and monocytic) and these
changes are associated with reduction in H3 acetylation patterns and
upregulation of HDAC1 and HDAC2. Genetic and pharmacological
approaches linked activity of HDAC1 to the altered expression of host
defense genes, suggesting the potential to modulate infection through
selective HDAC inhibition. This epigenetic mechanism involves Ankyrin
A, a type IV secretion system expressed by A. phagocytophilum that
interacts directly with HDAC1 (Rennoll-Bankert, Garcia-Garcia, Sinclair,
& Dumler, 2015).
The intracellular survival of M. tuberculosis involves reduced
responses to IFN-γ and an epigenetic contribution to this process was
suggested in the monocytic THP-1 cell line (Wang, Curry, Zwilling, &
Lafuse, 2005). HDAC inhibition with butyric acid or MS-275 reversed
the ability ofM. tuberculosisorMycobacteriumavium to block expression
of HLA-DRα or HLA-DRβ mRNA, IFN-γ responsive transcripts, while
mycobacterial infection inhibited IFN-γ induced histone acetylation. Al-
though transcription of HDAC1–3 was not altered byM. avium, the au-
thors demonstrated that mSin3A, which is present in a multi-
component complex with HDAC1 and HDAC2, and is a functional co-
repressor in HDAC-mediated inhibition of gene transcription, was up-
regulated. This provided evidence that mycobacteria can modulate
IFN-γ signaling through epigenetic mechanisms in addition to
established mechanisms, such as modulation of receptor expression or
signal transduction.
Other bacteria also modulate histone PTMs. In a model of murine
mastitis strains of S. aureus induced differing levels of H3K9 and
H3K14 acetylations, as well as differences in microRNA responses, and
those inducing higher levels of acetylationwere associatedwith greater
inﬂammatory responses and pathogen clearance (Modak et al., 2014).
The same group also suggested that these histone marks inﬂuenced
the inﬂammatory response to Escherichia coli in the same murine mas-
titis model (Modak et al., 2012).
It remains unclear what the consequences of epigenetic changes
during acute bacterial infections are. They can enable pathogen subver-
sion of the host immune response, but may also be used by the host to
modify transcriptional proﬁles, for example to limit thedamage induced
by sustained inﬂammation or to develop the trained response to
improve outcomes on re-exposure. If these consequences are better
delineated these processes could represent attractive therapeutic
targets in the future.
5.2. Epigenetics in sepsis
Sepsis deﬁnes a physiological state that results from a severe inﬂam-
matory responsemost often secondary to infectious process. It has been
responsible for 2 to 11% of all intensive care unit bed occupancy and is
associated with between 25 and 80% mortality (Angus & Wax, 2001).
The initial response to sepsis is pro-inﬂammatory with release of pro-
inﬂammatory cytokines predisposing to organ failure. This is driven by
the recognition of PAMPs or damage-associated molecular patterns
interactingwith TLR or other PRR, leading to activation of NF-κΒ depen-
dent genes and release of a variety of pro-inﬂammatory cytokines
(Foster & Medzhitov, 2009). The most well studied trigger of sepsis is
the response to LPS. It has been shown to lead to alterations in gene
expression mediated via epigenetic modiﬁcations (Foster et al., 2007).
This results in responses such as macrophage tolerance, which, as
described above, can have harmful effects through the associatedticmanipulation during infectious diseases, Pharmacology & Therapeu-
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an interesting therapeutic target.
5.3. Therapeutic targeting with histone deacetylase inhibitors in sepsis
There has been an increasing interest in the use of HDACi in sepsis.
However, their impact is unclear as they have been associated with
both promising survival beneﬁts but also impaired bacterial clearance.
When treating macrophages with broad spectrum HDACi, such as
suberoylandilide hydroxamic acid (SAHA) and TSA, macrophage's
microbial killing ability was impaired (Mombelli et al., 2011; Roger
et al., 2011). The macrophages exposed to HDACi had decreased levels
of ROS and NO, which impeded their microbiocidal responses to E. coli
and S. aureus. On the other hand, in mice the use of the HDACi
suberoylanilide hydroxamic acid (SAHA) is associated with clear
survival beneﬁts following cecal ligation and puncture (Li et al., 2010).
Similar results were seen in mice treated with Tubustatin (a HDAC 6
inhibitor), which was associated with enhanced resolution in
bacteraemia, less organ dysfunction and a modulated stress response
(Zhao et al., 2014). Thiswas associatedwith increasedmonocyte counts,
reversal of lymphopenia and increased neutrophil counts. Nevertheless,
the functional signiﬁcance of the association with monocyte counts
requires further clariﬁcation. Mice which received Tubustatin during a
hemorrhagic shock model were subsequently protected from sepsis
following cecal ligation and puncture in a two hit model of sepsis
(Cheng et al., 2015). Furthermore, mice treated with the SIRT1 and 2
inhibitor, Cambinol, were protected from endotoxic and toxic shock
(Lugrin et al., 2013).
Tubustatin enhanced macrophage generation of mitochondrial ROS
(mROS), a TLR generated microbicidal response in humanmacrophages
and increased intracellular killing of E. coli and Salmonella typhimurium
(Arifﬁn et al., 2015). Broad spectrum HDACi such as SAHA and TSA also
enhanced killing if administered at the time of bacterial challenge but
if incubated with macrophages for 18 h before bacterial challenge, they
reduced phagocytosis and overall impaired bacterial killing. A HDAC1–
3 inhibitor had no effect on bacterial killing, suggesting that speciﬁc
HDAC6 inhibition may be an important component of the modulation
of sepsis as shown by the clearance of bacteremia and improved out-
comes in mice, as shown by Zhao et al. (2014). This suggests that more
speciﬁc targeting of enzymes that regulate epigenetic changes may
enable improved responseswhile preserving keymicrobicidal responses.
6. Epigenetics in viral infection
Epigenetic changes are also seen in viral infections involving viruses
such as human adenovirus (Horwitz et al., 2008), inﬂuenza A (Marazzi
et al., 2012) and HIV (Han et al., 2012). The host cell restriction on
the replication of endogenous retroviruses also involves epigenetic
mechanisms. Recent evidence suggests an important role for the
histonemethyltransferase SET-domain bifurcated 1 (SETB1) in ensuring
H3K9me3 and repression of endogenous retrovirus replication in
differentiated B-cells from adult mice (Collins, Kyle, Egawa, Shinkai, &
Oltz, 2015).
Epigenetic modiﬁcations regulate the balance between viral latency
and replication as seen with herpes viruses (Kumar & Herbein, 2014). A
proteomics approach revealed that CMV replication in primary ﬁbro-
blasts resulted in several histone PTMs including increases in H3 lysine
79 dimethylation (H3K79me2) (O'Connor et al., 2014). This histone
PTM was associated with upregulation of its methyltransferase,
disruptor of telomeric silencing 1 like H3 lysine 79 methyltransferase
(DOT1L) and knockdown of DOT1L markedly reduced CMV replication.
CMV replication was also associated with an increase in H3 lysine 27
methylation/histone 3 lysine 36 dimethylation (H3K27meH3K36me2)
and a decrease in histone 4 lysine 16 acetylation (H4K16ac). During
human herpesvirus-8 infection SIRT1 helps maintain latency by pro-
moting the repressive mark H3 lysine 27 trimethylation (H3K27me3)Please cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013at the viral replication and transcription activator (He & Gao, 2014).
SIRT1 knockdown or chemical inhibition promoted lytic infection with
reduction of H3K27me3 and increases in the active H3K4me3 mark.
Enhanced H3K4me3 is also a feature of lytic infection with herpes
simplex virus where barrier to auto-integration factor 1 (BAF/BANF1)
a factor bridging chromosomes to the nuclear lamina was found to
play a role recruiting the histone methyltransferase (SETD1A) to
immediate-early and early gene promoters in the virus, facilitating rep-
lication (Oh et al., 2015). Therefore a picture is emerging of enzymes
that regulate histone PTMs at the site of viral gene promoters and either
allow or repress viral gene transcription.
6.1. Human immunodeﬁciency virus-1
HIV-1 is a single-stranded RNA virus, which replicates by reverse
transcription resulting in generation of a DNA duplex that integrates
into the host genome in CD4+ cells, mainly CD4+ T-lymphocytes
(Nisole & Saïb, 2004). Replication of the virus is dependent on host
cell-derived TFs and while activation enhances replication in some
cells, in long lived memory cells the HIV-1 virus can remain in a latent
state of relative transcriptional quiescence.
Anti-retroviral therapies (ARTs) aim to block replication principally
targeting key enzymes involved in reverse transcription, integration
and maturation of the HIV-1 proteins by the HIV-derived protease.
Therapeutic approaches also target steps involved in the entry process,
involving binding to the chemokine receptor CCR5 and fusion to the
plasma membrane (Arts & Hazuda, 2012). All existing approaches
involve life-long therapy and a therapeutic strategy that targets the
latent reservoir will be required if a therapeutic approach is to achieve
a cure (Deeks et al., 2012b). In view of the role of epigenetic mecha-
nisms in regulating viral latency discussed above modulating latency
through targeting of epigenetic regulation is perceived to be a vital
component of a strategy to deliver HIV cure.
6.2. Targeting the latent reservoir in
human immunodeﬁciency virus-1 infection
The latent HIV-1 reservoir persists within resting memory CD4+ T-
cells despite HAART (Siliciano et al., 2003). Reactivation of these resting
cells has been suggested as a central mechanism of HIV-1 persistence,
through viral transmission to uninfected activated CD4+ T-cells, despite
sustained ART (Chun et al., 2005). Epigenetic transcriptional interfer-
ence, via deacetylation and methylation of histones, antagonizes
binding of DNA polymerase and hence also restrict generation of
HIV-1 transcripts from the pro-viral DNA. The 5′ long terminal repeat
(5′ LTR) sequence of HIV DNA is bookended by nucleosomes Nuc-0
and Nuc-1, offering potent sites for inhibitorymodiﬁcation of transcrip-
tion. In particular, Nuc-1 is located in proximity to the transcription start
site (Verdin, Paras, & Van Lint, 1993). The chromatin and histones asso-
ciated with the 5′ LTR nucleosomes are subject to deacetylation and
trimethylation modiﬁcation by HDACs (Keedy et al., 2009) and histone
methyltransferases (HMTs) (Friedman et al., 2011) respectively. Epige-
neticmodiﬁcation by pro-viral DNAmethylation has also been shown to
exert an inﬂuence on latency in vitro (Blazkova et al., 2009) but has not
yet been shown in a clinical context (Blazkova et al., 2012a).
Manipulating histone PTMs to facilitate viral replication is one
component of the strategy termed ‘Shock and Kill’, with reversal of
latency though therapeutic modulation of epigenetic transcriptional
silencing and killing of the infected cells achieved by viral induced cell
cytotoxicity or alternatively by the immune response to viral proteins
produced during viral replication (Deeks, 2012a). There is no current
answer to how much pro-viral activation is necessary to achieve cell
death of the latently infected cells (Archin, Sung, Garrido, Soriano-
Sarabia, &Margolis, 2014b). Future approachesmust achieve controlled
levels of reactivation of latency without harmful immune activation.ticmanipulation during infectious diseases, Pharmacology & Therapeu-
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translational modiﬁcations in human immunodeﬁciency virus therapy
Recognition of the role of histone PTMs in mediating HIV-1 latency
provided several potential therapeutic targets. TheweakHDACi valproic
acid has been shown to increaseHIV-1 transcription frompro-viral DNA
and virus production in vitro from cultured cell lines with latent HIV-1
infection (Moog, Kuntz-Simon, Caussin-Schwemling, & Obert, 1996;
Witvrouw et al., 1997). However, when administered to individuals
with sustained suppression of viral replication, the majority of individ-
uals did not achieve a signiﬁcant reduction in the latent reservoir of
CD4+ T-cells (Archin et al., 2008).
SAHA (vorinostat), like valproic acid has also enhanced HIV-1
replication (Archin et al., 2009a). Vorinostat targets several classes of
HDACs, including class I HDACs. This group of HDACs inhibits transcrip-
tion, through deacetylation of the lysine tail of core histones, so that
access to DNA by TFs is antagonized, as well as by recruiting additional
transcription-repressing histone-modifying complexes (Archin, et al.,
2009b). A clinical trial identiﬁed sixteen aviremic (HIV viral load
b50 copies/ml) patients of whom eleven had evidence of vorinostat-
induced increases in HIV RNA in puriﬁed resting memory CD4+ T-cells
isolated by leukapheresis. Of these, eight patients stable onART received
an initial dose of 200mgvorinostat to establish safety, and subsequently
a single 400 mg dose (Archin et al., 2012). Total cellular H3 acetylation
increased (median 1.6-fold, p b 0.01) in resting CD4+ T-cells isolated
6 h after drug exposure, in which HIV RNA expression also increased
by a mean of 4.8-fold (range 1.5–10, p b 0.01). However, a diminishing
response to successive vorinostat treatment was observed when
administered on three successive days over eight weekly cycles
(Archin et al., 2014a). Importantly, vorinostat was well tolerated by all
with no adverse events reported.
The proof of concept that HDACi can increase viral replication from
latent reservoirs has spurred experimentation with alternative and
more selective HDACi. Antagonism of class I HDACs induced the desired
acetylation of LTR-associated histones, whereas antagonism of class II
HDACs had no signiﬁcant effect (Archin, et al., 2009b). A number of
alternative inhibitors with activity against class I HDACs, namely
panobinostat, givinostat and belinostat, are in development as oncology
therapies and may offer greater potency in vivo than vorinostat
(Rasmussen et al., 2013). Panobinostat is a pan-HDAC inhibitor, has
activity against classes I, II and IV HDACs (Prince & Bishton, 2009). In
vitro it induced HIV RNA expression in latently infected cell lines
(Rasmussen et al., 2013). A phase I/II trial, CLEAR,was recently completed
(Rasmussen et al., 2014). Volunteers received 20mgpanobinostat three
times per week every other week. Intracellular HIV RNA and DNA
expression signiﬁcantly increased, alongside detectable increases in
HIV peripheral copy number in the blood. However, estimates of the
number of cells with latent infection remained unchanged, suggesting
limitations with the HDAC inhibitor strategy for reduction of the
HIV-1 reservoir as currently employed.
The epigenetic mechanism by which post-integration pro-viral
latency develops could be targeted in combination with approaches to
increase TF availability. Activation of cytoplasmic NF-κΒ by the phorbol
ester prostratin stimulates its translocation to the nucleus, where it
activates HIV transcription (Williams et al., 2004). Valproic acid or
vorinostat used in combination with prostratin displayed synergistic
activation of latent provirus (Reuse et al., 2009). These in vitro models
of latently infected cells demonstrated HDACi increased prostratin-
dependent effects on the NF-κΒ binding capacity, promoting activation
of the 5′ LTR of HIV and transcription of virus.
Histone lysine methyltransferase (HKMT) inhibitors have also been
investigated as a potential therapeutic option. Methylated H3 has
been demonstrated to be dimethylated (Imai, Togami, & Okamoto,
2010) and trimethylated (Pearson et al., 2008) at speciﬁc locations
that interact with latent HIV-1 genomes, and have been considered re-
pressive in other epigenetic settings (Kouzarides, 2002). KnockdownPlease cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013of the HKMT G9a, responsible for the dimethylation of H3 lysine 9
(H3K9me2), and knockdown of the HKMT enhancer of Zeste 2 (EZH2)
permits increased accessibility of the HIV 5′ LTR, allowing viral tran-
scription (Imai et al., 2010; Friedman et al., 2011). EZH2 is a subunit of
the polycomb repressive complex 2 (PRC2) andmediates gene silencing
through PTM of histones. It is required for the enzymatic function that
induces the trimethylation of H3 lysine 23 (H3K27me3). The speciﬁc
HKMT G9a antagonist BIX01294 enhanced HIV-1 gene expression
when applied to latently infected T-cells in vitro and CHIP-seq identiﬁed
G9a and H3K9me2 in the vicinity of the HIV-1 promoter region (Imai
et al., 2010). In vitro assays in latently infected ACH-2 cells also revealed
synergy between BIX01294 and vorinostat, increasing HIV-1 gene
expression individually from 4.9-fold and 13.5-fold respectively to
47.1-fold when in combination. Furthermore, the combination of
BIX01294 and the DNA methylation inhibitor 5-aza-2′-deoxycytidine
(aza-CdR), which individually increased viral replication by 7.0-fold
and 8.5-fold respectively, resulted in an increase in viral transcription
to 29.6-fold (Imai et al., 2010). A pan-HKMT antagonist, 3-
deazaneplanocin-A (DZNep) has been shown to be superior to
BIX01294 in subsequent in vitro experiments utilizing a latently
infected E4 cell line. E4 cells exposed overnight to BIX01294 and
DZNep induced pro-viral expression in 21.1% and 31.5% of cells respec-
tively (Friedman et al., 2011). Synergy between DZNep and vorinostat
was also displayed after 48 h in experiments using 5 μMDZNep applica-
tion followed by 0.5 μM vorinostat, with 15.3% and 4.2% respective
inductions of latent viral expression when the agents were used
individually compared to 29.3% when in combination (Friedman et al.,
2011).
Targeting DNA methylation might represent a further epigenetic
approach to target HIV latency on the basis of in vitro experiments.
CpG hypermethylation of the 5′ LTR promoter and enhancer sequences
confers transcriptional silencing that contributes to the establishment of
the stable latent reservoir and develops as a late event when compared
to transcriptional interference and chromatin modiﬁcation (Blazkova
et al., 2009). A cDNA library screen identiﬁed methyl-CpG binding
domain protein 2 (MBD2) as a factor promoting HIV-1 latency
(Kauder, Bosque, Lindqvist, Planelles, & Verdin, 2009). Inhibition of cy-
tosine methylation with the DNA methylation inhibitor 5-aza-2′-
deoxycytidine (aza-CdR) in vitro reduced recruitment of MBD2 and
HDAC2 to an immortalized CD4+ T-cell, which is latently infected
with the complete HIV-1 genome that is transcriptionally inhibited by
hypermethylation at the promoter region. When used in combination,
aza-CdR plus the NF-κΒ activator prostratin, stimulated greater HIV-1
expression in the immortalized CD4+ T-cell, compared to prostratin
alone (Kauder et al., 2009). The combination of aza-CdRwith vorinostat
demonstratedweak synergism, but independent application of aza-CdR
showed no increase in HIV-1 expression. The authors were also able to
demonstrate methylation of HIV-1 CpG islands and latency in primary
memory CD4+ T-cells. However, others have suggested latently infect-
ed resting CD4+ cells isolated from patients fully suppressed with ART
only rarely display hypermethylation of the 5′ LTR sequence,
questioning the potential utility of methylation inhibitors (Blazkova
et al., 2012b).
7. Future drug targets and potential
As discussed above, there have been a number of different
pharmacological compounds used in vitro and in vivo to modulate
the epigenome. These range from HDACi, bromodomain inhibitors
(Heerboth et al., 2014) and novel CRISPR/Cas9 coupled methyl-
transferases and acetylases (discussed below) (Hilton et al., 2015).
HDACis have been used more extensively to date (see Table 2 for use
in HIV trials), indeed several of them are now licensed for use in
cutaneous T-cell lymphoma and multiple myeloma. There are 18
different kinds of HDACis in humans, which are divided into 4 classes
based on their homology with yeast HDACis. However, as alluded toticmanipulation during infectious diseases, Pharmacology & Therapeu-
Table 2
Clinical trials of HDACi in HIV eradication.
Category Name Clinical Trial ID Status/estimated
completion date
Details Sponsor
HDACi Valproic acid NCT00614458 Terminated
(September 2008)
10,493 — MK-0518 intensiﬁcation and HDAC inhibition
in depletion of resting CD4+ T-cell HIV infection
University of North Carolina,
Chapel Hill
HDACi Romidepsin NCT01933594 Recruiting/May 2016 Phase I/II trial; evaluating the safety and efﬁcacy of
single-dose romidepsin in combination with ART in
HIV-1 infected adults with suppressed viral load
National Institute of Allergy and
Infectious Diseases (NIAID)
HDACi Romidepsin NCT02092116 Ongoing, recruitment closed/
December 2015
An open phase I/IIa study to evaluate the safety and efﬁct
of therapeutic HIV-1 immunization using vacc-4× +
rhuGM-CSF, and reactivation using romidepsin on the
viral reservoir in virologically suppresed HIV-1 infected
adults on ART. (REDUC)
Bionor Immuno AS
HDACi Panobinostat NCT01680094 Completed (January 2014) The safety and efﬁcacy of the HDACi panobinostat for
purging HIV-1 for the latent reservoir (CLEAR) study
University of Aarhus
HDACi Panobinostat NCT02471430 To start (September 2015)/
February 2020
A phase II pilot study to assess the safety and efﬁcacy of
combined treatment with pegylated interferon-alpha2a
and the HDACi panobinostat for reducing the residual
reservoir of HIV-1 infected cells in ART-treated HIV-1
positive individuals (ACTIVATE).
Massachusetts General Hospital
HDACi Vorinostat NCT01319383 In progress/March 2016 A phase I/II investigation of the effect of vorinostat on
HIV RNA expression in resting CD4+ T-cells of
HIV-infected patients receiving stable ART
University of North Carolina,
Chapel Hill
HDACi Vorinostat NCT02336074 To start (September 2015)/
July 2018
Research in viral eradication of HIV reservoirs (RIVER);
prospective RCT comparing raltegravir boosted HAART
with or without ChAd prime + MVA boost HIV vaccine
+28 day course of vorinostat
Imperial College London
HDACi Vorinostat NCT02475915 Recruiting/April 2016 A randomized study to compare efﬁcacy of
vorinostat/hydroxychloroquine/maraviroc (VHM) in
controlling HIV after treatment interruptions in subjects
who initiated ART during acute HIV infection.
South East Asia Research
Collaboration with Hawaii
10 J. Cole et al. / Pharmacology & Therapeutics xxx (2016) xxx–xxxearlier, the impact of HDACis on innate immune function is mixed, they
both help with the resolution of inﬂammation but also impair the
microbiocidal functions of macrophages in some settings. Moreover,
most of these studies have used pan-HDACis that have many off target
effects and it is likely that the more speciﬁc novel treatments will
allow for improved targeting. Strategies targeting site speciﬁc histone
PTMs such as the Jumonji H3K27 demethylase inhibitor (GSK-J1/J4)
which was shown to modify the post-LPS inﬂammatory response
(Kruidenier et al., 2012), may allow these problems to be circumvented
by decreasing the off target effects. Indeed HDACs have a diverse
number of target proteins including structural proteins such as α-
tubulin, DNA-binding nuclear receptors, transcription regulators and
signaling mediators, both inside the nucleus but also in the cytoplasm.
Furthermore, HDACs can also exert their activity on other HDACs as
part of larger multiprotein complexes (Falkenberg & Johnstone, 2014);
hence it is difﬁcult to distinguish the speciﬁc site of action of broad
HDACis. Most of the older HDACis, such as SAHA or TSA, target several
different HDACs. Therefore the exact biological consequences are hard
to untangle. More recently, isoform selective HDACis have been
developed such as HDAC 6 inhibitor Tubastatin A (Vishwakarma et al.,
2013). This may explain themixed results of HDACis in sepsis as earlier
trials used the less selective compounds inhibiting both classes I and II
HDACs whereas the HDAC6 inhibitors hadmore positive results. Indeed
as further compounds with greater selectivity are developed this will
allow greater manipulation of individual epigenetic pathways.
The bromodomain inhibitors may also allow speciﬁcity in targeting
and allow for individual histone PTMs to be manipulated in a dynamic
fashion during the course of infection or inﬂammation. The
bromodomain and extra terminal domain family of proteins (BET) act
as adaptors that link histone acetylation status to transcription by
incompletely deﬁned mechanisms (Smale et al., 2014). However, the
majority of all the BET proteins seem to act by a mechanism that
involves the RNA elongation complex polymerase associated factor 1
complex that plays a role in RNA initiation and also elongation
(Dawson et al., 2011). The ET domain of the BET proteins interactsPlease cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013with various proteins likely to inﬂuence chromatin remodeling
including NSD3 (a SET-domain-containing histone methyltransferase)
and JMJD6 (Rahman et al., 2011). The precise role of JMJD6 remains
unclear; it was initially thought to be a histone arginine demethylase
(Chang, Chen, Zhao, & Bruick, 2007) but more recently has been de-
scribed as a hydroxylase involved in regulating RNA splicing (Webby
et al., 2009). The bromodomain inhibitors would be predicted to act at
the CpG low promoters and allow modulation of some of the most po-
tent LPS responses that result in induction of IL-6, IL-12 and NO,
which could have advantages in downregulating systemic inﬂammation
during severe infections (Smale et al., 2014). The speciﬁc bromodomain
inhibitor JQ1 has been successfully used in murine models of myeloma
to modulate the function of the oncogene c-Myc (Delmore et al.,
2011). This suggests that a more targeted approach using these agents
is possible. In an alternative but related approach a synthetic inhibitor
that interferes with the recognition of histone acetylation by the BET
family of proteins, and thus the formation of the complex driving
mRNA generation from the associated gene, was shown to be capable
ofmodulating the response to LPS (Nicodeme et al., 2010). The inhibitor
(I-BET), a synthetic histonemimic, reduced the induction of a number of
inﬂammatory cytokines (including IL-6, Interferon-β, IL-1β) by
activatedmurinemacrophages following LPS stimulation. Furthermore,
this effect was selective for inﬂammatory responses, as the expression
of housekeeping genes was not modiﬁed. I-BET also demonstrated
efﬁcacy in reducing the death rate in mice following LPS challenge or
bacterial sepsis and therefore holds promise as a novel approach
regulating the inﬂammatory response. More recently, these results
have been reproduced in primary human macrophages. The authors
demonstrated that I-BET151 led to decreased IFN responses following
TLR4 and TNF-α stimulations (Chan et al., 2015).
Recent advances in the ﬁeld of clustered regularly interspaced short
palindromic repeats (CRISPR) technology have enabled targeted modi-
ﬁcation of the epigenome in an effort to manipulate gene regulation
(Fig. 2). The CRISPR–Cas9 editing system has enabled researchers to
target a speciﬁc location in the genome, therefore enabling the detailedticmanipulation during infectious diseases, Pharmacology & Therapeu-
HDACi:
(I.E. TSA, 
Tubastatin, 
SAHA, etc.)
Gene transcriptionHDACi
HDAC Repressed gene transcription
BET inhibitors:
(I.E. JQ1 & I-BET)
BET Gene transcription
Repressed gene transcription
a)
b)
c)
CRISPR/CAS9:
CRISPR/CAS9
Repressed gene transcription
Gene transcription
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Nucleosome
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Histone deacetylase inhibitor
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Bromodomain inhibitor
CRIPSR/Cas9 coupled 
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Legend:
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HDAC
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CRISPR/CAS9
Fig. 2. a) Schematic representation of the mode of action of HDACi. Leading to the maintenance of the acetyl post-translational modiﬁcation and thereby ongoing gene transcription.
b) Schematic representation of bromodomain inhibitors such as I-BET151 or JQ1, these inhibit the binding of bromodomains such as BRD4 to the underlying chromatin thereby
inhibiting gene transcription. c) Schematic representation of the mode of action of CRISPR/CSAS9 construct, this leads to the acetylation of the promoter region of a speciﬁc gene
leading to its transcription.
11J. Cole et al. / Pharmacology & Therapeutics xxx (2016) xxx–xxxanalysis of the function of speciﬁc epigenetic changes. The CRISPR–Cas9
systems are a more robust and high throughput approach, compared to
previous methods (Ledford, 2015).
An inactive Cas9 (CRISPR-associated protein 9) was used as a
programmable CRISPR/CAS9 construct fused with an acetyltransferase
(p300) allowing the acetylation of the promoter region of speciﬁc
genes (Hilton et al., 2015). The fusion protein catalyzes the acetylation
of H3K27 at its target sites, leading to transcriptional activation of target
genes. The results of this study supported targeted acetylation as a
causal mechanism of transactivation (Hilton et al., 2015).
The CRISPR–Cas9 system has also been used to with a deactivated
Cas9 enzyme fused to LSD1 (a histone demethylase), and subsequently
programmed to target regions of DNA believed to enhance the expres-
sion of a range of genes (Kearns et al., 2015). The result was a functional
map of genetic ‘enhancer’ sequences that provided further insight into
enhancer regions and their genomic locations.
This ground-breaking development paves the way for a reversible
editing of the epigenome and thereby a speciﬁc approach targeting
cell function by inﬂuencing gene expressionwithout altering the under-
lying DNA. This could lead to the targeted resolution of inﬂammatory
processes or to the manipulation of individual epigenomes to reduce
the susceptibility to disease or prevent the relapse of malignancies. Fu-
ture work, focusing on a range of alternative chromatin modiﬁers and
orthogonal dCas9 systems will allow researchers to perform even
more complex epigenome engineering.
8. Conclusion
In conclusion, it is apparent that our increased understanding of how
chromatin remodeling inﬂuences immune function and specialization
has opened up the therapeutic potential of the area. Initial approaches
to modulate systemic inﬂammation in sepsis and to reactivate HIV
from latency show the potential of the approach. In addition the
development of site speciﬁc and more potent HDACi, bromodomain
inhibitors and CRISPR technology offer powerful tools with which to
exploit the potential modulation of histone PTMs regulating gene
transcription in the management of infectious diseases. Finally
pathogens themselves may express enzymes to modify histone PTMs
and regulate gene transcription. These may then provide potentialPlease cite this article as: Cole, J., et al., The therapeutic potential of epigene
tics (2016), http://dx.doi.org/10.1016/j.pharmthera.2016.07.013therapeutic targets if selective inhibitors can be identiﬁed as evidenced
by potential interest in inhibiting P. falciparum HDACs to limit parasite
growth and development (Andrews et al., 2012). Thus modulation of
histone PTM may offer a range of potential therapeutic options in the
future.
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